To compare the efficacy and safety of weekly albiglutide with daily sitagliptin, daily glimepiride, and placebo.
The management of type 2 diabetes has become an increasingly complex practice given the number of treatments available (1) . Despite the availability of new therapeutic agents, many patients with type 2 diabetes continue to have uncontrolled glycemia (2) (3) (4) , and treatment adherence varies but remains relatively poor (5) (6) (7) (8) (9) .
Among patients taking metformin but who do not have adequately controlled diabetes, data are limited regarding next-step concomitant treatment (10) . As a result, extended head-to-head comparisons of type 2 diabetes medications mirroring treatment algorithms (i.e., combinations with metformin) are needed to aid clinicians in making treatment decisions (11, 12) . Recent treatment guidelines have positioned incretin-based therapies, such as GLP-1 receptor agonists (GLP-1RAs), as alternative first-line therapies in certain clinical settings and as second-line therapies following metformin because of their substantial effectiveness in improving glycemic control as well as other positive effects, such as weight loss and low hypoglycemia rates (10, 13, 14) .
Albiglutide is a novel, once-weekly, long-acting GLP-1RA composed of a dipeptidyl peptidase-4 (DPP-4)2resistant GLP-1 dimer fused to recombinant human albumin. This structure affords an extended half-life of ;5 days and, as a consequence, once-weekly dosing (15, 16) . In a multinational phase 2b study of type 2 diabetes, albiglutide 30 mg once-weekly reduced HbA 1c by 20.87% (29.5 mmol/mol) and also reduced fasting plasma glucose (FPG) and weight, with a low incidence of gastrointestinal (GI) adverse events (AEs) (16) .
The HARMONY program for albiglutide includes eight pivotal phase 3 studies designed to evaluate the efficacy and safety of albiglutide compared with placebo, oral antidiabetic medications, insulin glargine, and another GLP-1RA in a typical type 2 diabetes population (17, 18) . Here, we present 2-year primary end point data for HARMONY 3, which is a 3-year phase 3 study comparing the efficacy and safety of weekly albiglutide with daily sitagliptin, daily glimepiride, and placebo in patients with diabetes receiving metformin but not adequately controlled by the medication.
RESEARCH DESIGN AND METHODS

Study Design
This was a phase 3, randomized, doubleblind, placebo-and active-controlled parallel-group study that occurred between 17 February 2009 and 21 March 2013; the study comprised 4 study periods: screening, run-in/stabilization (4 weeks), treatment (156 weeks; 104-week data are reported here), and posttreatment follow-up (8 weeks) (Fig. 1A) ; creatinine clearance .60 mL/min (determined using the Cockcroft-Gault formula); and normal thyroid-stimulating hormone concentration or were clinically euthyroid.
Exclusion Criteria
Major exclusion criteria were current ongoing symptomatic biliary disease or history of pancreatitis, recent clinically significant cardiovascular and/or cerebrovascular disease (#2 months before screening), treated gastroparesis, history of GI surgery thought to significantly affect upper GI function, history of most cancers not in remission for at least 3 years, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, resting systolic blood pressure (SBP) .160 mmHg and/or diastolic blood pressure (DBP) .100 mmHg, lipase above the upper limit of normal (ULN), hemoglobinopathy that could affect HbA 1c , and alanine aminotransferase or aspartate aminotransferase more than two and a half times the ULN.
Withdrawal Criteria
Patients withdrew or were removed from the study drug because of loss to followup, protocol violation, noncompliance, withdrawal of consent, or an AE or laboratory result requiring withdrawal, including QTc prolongation, elevation of liver function test results, severe potential allergic reactions, confirmed pancreatitis, severe or repeated hypoglycemia, and calcitonin .100 pg/mL. All major CV AEs occurring postrandomization were adjudicated by a clinical end point committee and are part of an ongoing meta-analysis (results will be reported separately). An independent, blinded pancreatitis adjudication committee (PAC) comprising three GI specialists adjudicated AEs suggesting pancreatitis and all laboratory elevations of lipase and/or amylase more than or equal to three times the ULN. The PAC adjudicated both the probability of events being pancreatitis (definite, probable, possible, not likely) and the likelihood of a relationship to the study drug (definite, probable, possible, unlikely alternate etiology).
To assess any association of study medication with potential SARs, investigators flagged AEs that were considered SARs. Additional evaluation of the AE data for SARs was conducted using standardized Medical Dictionary for Regulatory Activities queries for angioedema, anaphylaxis, and severe cutaneous reaction. Hypoglycemia was defined and assessed using American Diabetes Association criteria (19) and evaluated before hyperglycemic rescue.
Statistical Methods
The planned sample size provided .90% power to demonstrate superiority versus placebo and noninferiority versus sitagliptin and glimepiride (noninferiority margin = 0.3%). Superiority of albiglutide versus sitagliptin and glimepiride was tested if noninferiority was established. The primary efficacy end point (intent-to-treat population/last observation carried forward algorithm) was analyzed using an ANCOVA model to compare treatment effects adjusting for region, history of previous MI, age category, and baseline HbA 1c . Patients rescued from hyperglycemia before week 104 had their latest HbA 1c value before rescue carried forward for primary analyses. Those patients who achieved treatment goals were evaluated by nonparametric ANCOVA. Time to rescue was evaluated by KaplanMeier curves and log-rank tests. For primary end point analysis, log-rank tests for the duration up to the primary end point were added post hoc. A multiple comparisons adjustment strategy was implemented for various inferential tests among the primary and key secondary objectives; AEs were analyzed by incidence proportion and incidence density rate overall and before rescue (with additional type 2 diabetes medication); in this article, overall incidence/rate is used for all events except hypoglycemia.
Study Conduct
This study was conducted in accordance with good clinical practice standards, all applicable privacy requirements, and the guiding principles of the Declaration of Helsinki. Written informed consent was obtained from each patient before participation.
RESULTS
This study was conducted at 289 centers in 10 countries. Demographics and baseline characteristics were similar among the albiglutide (n = 302), glimepiride (n = 307), sitagliptin (n = 302), and placebo (n = 101) treatment groups (Supplementary Table 1 ).The mean age for the groups ranged from 54.3 to 56.1 years (84.3% were ,65 years old); approximately half of patients were men and the majority were white (63.4-74.5%). Approximately 67.0% of the total population were moderately to severely obese (BMI $30 kg/m 2 ); mean weight in all treatment groups ranged from 89.6 to 91.8 kg, and mean duration of diabetes ranged from 5.8 to 6.7 years. In all treatment groups at baseline, HbA 1c levels were similar (8. Overall, 67.4% of patients completed active treatment through week 104; rates of completion were similar among the active treatment groups (sitagliptin 67.7%, glimepiride 68.8%, and albiglutide 68.3%) and lower for the placebo group (59.6%). The main reasons for discontinuing active treatment were withdrawal of consent (placebo 14.4%, sitagliptin 13.1%, glimepiride 13.2%, albiglutide 12.1%) and AEs (placebo 4.8%, sitagliptin 3.2%, glimepiride 4.1%, albiglutide 6.3%). Patient flow is presented in Fig. 1B .
Although all treatment groups went through a blinded up-titration procedure, only the albiglutide and glimepiride groups actually up-titrated to 50 and 4 mg, respectively. By week 104, a higher proportion of patients went through the blinded up-titration process in the placebo (;69%) and sitagliptin (;59%) groups compared with the glimepiride (;54%) and albiglutide (;53%) groups. Mean doses for albiglutide and glimepiride at week 104 were 40.5 and 3.1 mg, respectively. Fig. 1) . The difference between albiglutide and the comparators was statistically significant for placebo at all threshold levels (P # 0.02) and was comparable with only sitagliptin and glimepiride at the ,7.5% (,58.5 mmol/mol; P # 0.04) level. For the albiglutide group, these treatment thresholds were met by 17.1%, 38.6%, and 58.7% of patients, respectively. Subgroup analyses for age, race, ethnicity, sex, baseline BMI, and baseline HbA 1c were all consistent with the primary end point (Supplementary Fig. 2) . 
Secondary Outcomes
FPG
Changes in FPG from baseline at week 104 were consistent with the primary end point (Fig. 2C) (Fig. 2D ).
Time to Hyperglycemic Rescue
The albiglutide group had the most durable glycemic control. Per KaplanMeier estimates, fewer patients received hyperglycemic rescue in the albiglutide group (25.8%) compared with the placebo (59.2%), sitagliptin (36.4%), and glimepiride groups (32.7%). The difference between baseline and time to rescue with albiglutide was statistically significantly longer compared with sitagliptin (P = 0.0118) and placebo (P , 0.00001) (Fig. 3) .
General Safety and Tolerability
For overall safety, the proportion of patients experiencing AEs, SAEs, and AEs leading to withdrawal while receiving therapy was relatively balanced among treatment groups (Table 1) . Most AEs were mild or moderate in intensity in all treatment groups. The most frequent AEs (occurring in .7% of patients taking albiglutide) were upper respiratory tract infection, diarrhea, nausea, injection-site reaction, hypertension, nasopharyngitis, and cough. The type of AEs overall and those occurring before rescue (i.e., before the addition of hyperglycemic rescue medication) were similar, and the majority of AEs occurred before rescue (Supplementary Table 2 ). The rate of AEs was higher with albiglutide and generally due to the higher rate of injection-site reactions (45 of 100 patient-years for albiglutide vs. 1 of 100 patient-years for placebo). Fewer patients experienced SAEs in the albiglutide group (12.9%) than in the placebo group (15.8%) but were comparable with those who experienced SAEs in the sitagliptin and glimepiride groups (9.9% and 11.7%, respectively). Overall, eight fatal SAEs occurred through week 104 (three each for albiglutide and glimepiride and one each for sitagliptin and placebo); none were considered by the investigators to be related to study medication.
Events of Special Interest (Through Week 104)
GI Events GI AEs were experienced by a similar proportion of patients in the albiglutide (n = 110; 36.4%) and placebo groups (n = 38; 37.6%) and fewer in the sitagliptin (n = 75; 24.8%) and glimepiride groups (n = 85; 27.7%). Few GI events were severe in intensity (1.0%, 1.3%, 1.3%, and 4.0% for placebo, sitagliptin, glimepiride, and albiglutide, respectively) or led to withdrawal of the study drug (1.0%, 1.0%, 0.7%, and 2.0%, respectively). The most common GI event was diarrhea in the sitagliptin, glimepiride, and albiglutide groups and constipation in the placebo group. At week 104, nausea event rates were comparable between treatment groups (7.9, 5.3, 3.7, and 9.3 events per 100 patient-years for placebo, sitagliptin, glimepiride, and albiglutide, respectively), even though the incidence was highest in the placebo group (10.9%) compared with sitagliptin (6.6%), glimepiride (6.2%), and albiglutide (10.3%). The incidence and event rate of vomiting over the 104 weeks was (5.6%, 4.4 events per 100 patientyears) in the albiglutide group compared with placebo (1.0%, 0.6 events per 100 patient-years), sitagliptin (4.3%, 3.2 events per 100 patientyears), and glimepiride (3.6%, 2.1 events per 100 patient-years). The per-visit prevalence of nausea/vomiting among patients receiving albiglutide was ,5% at each time point (Supplementary Fig. 3 ).
Hypoglycemia
Documented symptomatic hypoglycemia (#3.9 mmol/L [#70 mg/dL]) before rescue with albiglutide was low (3.0%) and was similar to placebo (4.0%) and sitagliptin (1.7%) compared with glimepiride (17.9%) ( Table 1) . No severe hypoglycemic events were reported before rescue.
Injection-Site Reactions
Events classified by investigators as injection-site reactions occurred more frequently with albiglutide (17.2%; n = 52) compared with glimepiride (7.8%; n = 24), sitagliptin (6.3%; n = 19), and placebo (5%; n = 5). Injection-site reactions for albiglutide were mostly mild to moderate in intensity (98.1%), were not progressive, and most patients (n = 32/ 52; 61.5%) experiencing injection-site reactions had 1 or 2 events that lasted #1 week (median duration). These reactions led to the withdrawal of 4 of 302 patients (1.3%) at 2 years. Most patients (41 of 52; 79.0%) treated with albiglutide who experienced injection-site reactions were negative for antialbiglutide antibodies.
Pancreatitis
Six patients (albiglutide, n = 4; glimepiride, n = 2) were evaluated by a blinded, independent PAC because of a reported AE or a lipase/amylase concentration more than or equal to three times the ULN. Adjudication determined that neither patient from the glimepiride group had pancreatitis. Among the four patients receiving albiglutide, adjudication determined that one event was unlikely to reflect pancreatitis, one event was considered to reflect possible pancreatitis (laboratory elevations alone) unlikely related to the study drug, and two events were probable pancreatitis (laboratory elevations and suggestive symptoms), and both were considered possibly related to the study drug.
Thyroid Cancer
One patient treated with albiglutide developed follicular cancer on day 243.
Two patients receiving sitagliptin developed thyroid cancer: one experienced follicular papillary carcinoma on day 48 and the other papillary thyroid cancer on day 549. In these three patients, thyroid cancer diagnoses were considered by the investigator to be not related to the study drug, and calcitonin concentrations were not abnormal.
Potential SARs
A search of the standardized Medical Dictionary for Regulatory Activities queries identified two patients (placebo, n = 1; glimepiride, n = 1) who experienced angioedema as an SAE. The investigator considered neither to be related to the study drug but instead related to ACE inhibitor therapy. Both patients remained in the study after discontinuing ACE inhibitor therapy. Neither patient had positive antialbiglutide antibodies, and no other cases of angioedema, anaphylaxis, pharyngeal edema, or laryngeal edema occurred. The investigators did not flag any additional events of interest.
Immunogenicity
Antialbiglutide antibody incidence among albiglutide-treated subjects was 7.0% (21 of 302 subjects), and included 1 subject (0.4%) with preexisting antibodies (positive at baseline). Antibodies were nonneutralizing and showed reactivity with GLP-1 in 16 of the 21 antibody-positive subjects and with albumin in 5 antibody-positive subjects. No samples tested positive for antialbiglutide IgE antibodies, and no SARs were reported for antibody-positive subjects.
Cardiovascular Parameters
At baseline, lipids and blood pressure were well controlled and mean values were similar across the four treatment groups (Supplementary Table 3 ). There were no clinically meaningful mean changes to lipids throughout the study. Minor changes in SBP and DBP, respectively, from baseline occurred in all treatment groups at week 104: placebo (2.2 and 0 mmHg), sitagliptin (0.2 and 0.2 mmHg), glimepiride (1.5 and 1.0 mmHg), albiglutide (21.0 and 20.7 mmHg). Treatment differences in SBP and DBP at week 104 between albiglutide and the three comparators were not statistically significant. Similarly, there were no meaningful changes from baseline at week 104 in mean heart rate: placebo, 2.3 bpm; sitagliptin, 0.8 bpm; glimepiride, 20.5 bpm; albiglutide, 1.3 bpm.
CONCLUSIONS
When added to metformin, albiglutide produced clinically and statistically superior and more sustained reduction in HbA 1c at week 104 compared with Data are incidence (percentage of patients with event) and event rate (events per 100 person-years). The order of AEs is based on albiglutide proportion in the overall data. *Patients with more than one hypoglycemic event were counted in all severity categories reported. Percentages are based on the number of patients in each treatment group for the study being summarized. Severity was derived using the American Diabetes Association guidelines for categorization of hypoglycemic events, as follows: severe = required assistance of another person; documented symptomatic = typical symptoms accompanied by a plasma glucose concentration of #3.9 mmol/L; and asymptomatic = no symptoms but plasma glucose concentration #3.9 mmol/L.
placebo, sitagliptin, and glimepiride. The sustained treatment effect of albiglutide also is supported by the time to hyperglycemic rescue, which showed that fewer subjects taking albiglutide required rescue by week 104 compared with patients treated with placebo, sitagliptin, and glimepiride; the difference was statistically significant for albiglutide versus placebo and sitagliptin. Interestingly, the reduction in HbA 1c was similar during the early treatment period (;4 weeks). This might not have been anticipated given the longer time to a steady state for the once-weekly albiglutide and the quick mechanism of action of sulfonylureas. Similar clinically and statistically superior results with albiglutide compared with all other treatment arms were observed for change in FPG from baseline and the proportion of patients meeting clinically relevant HbA 1c treatment goals. In addition, patients receiving albiglutide, sitagliptin, and placebo lost weight through week 104, whereas patients treated with glimepiride gained weight; the difference between albiglutide and glimepiride was statistically significant (P , 0.0001). The sustained effect of diabetes therapy is a critical clinical issue. Previous type 2 diabetes comparator trials have demonstrated the superiority or noninferiority of GLP-1RAs with or without metformin but have been shorter 26-week trials (20) (21) (22) . The Diabetes Therapy Utilization: Researching Change in A1C, Weight, and Other Factors Through Intervention with Exenatide OnceWeekly (DURATION)-2 and Liraglutide Effect Action in Diabetes (LEAD)-2 trials, which included metformin in all treatment arms, demonstrated the superiority of exenatide over sitagliptin and pioglitazone and of liraglutide over placebo, respectively, with regard to HbA 1c reductions (20) (21) (22) . In another 26-week study (HARMONY 8) , once-weekly albiglutide provided superior glycemic improvement, similar tolerability, and better patient compliance compared with sitagliptin therapy in patients with type 2 diabetes and renal impairment (21) . Understanding the long-term effects on type 2 diabetes of different combination therapies has led to the 5-year Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study. This trial is comparing the efficacy and durability of four classes of medications (DPP-4, sulfonylureas, GLP-1RAs, and long-acting insulin) in patients with type 2 diabetes who are receiving metformin (11). The results reported here may give a window to the eventual results of that trial.
Albiglutide was generally well tolerated; the albiglutide group showed rates of SAEs and AEs leading to withdrawal similar to those of the comparator groups. The percentage of patients reporting AEs while receiving therapy was similar for albiglutide, sitagliptin, and glimepiride and slightly lower for placebo. The types of AEs noted for albiglutide are generally consistent with the type 2 diabetic population and the known profile of GLP-1RAs (23, 24) .
The 104-week incidence of nausea/ vomiting with albiglutide (10.6%/5.6%) was lower than values observed in previous studies using other GLP-1RAs, particularly in the early weeks of therapy. In clinical practice, GI AEs occurring early in the course of treatment with GLP-1RAs may contribute to the discontinuation rates seen with this class, and agents with reduced GI effects may improve patient adherence. With respect to hypoglycemia, albiglutide had rates similar to sitagliptin and placebo and lower rates compared with glimepiride. Injection-site reactions were more common in the albiglutide-treated subjects, although a few (1.3%) withdrew because of reactions during the 104-week period. The proportion of patients developing antialbiglutide antibodies was low, and none were nonneutralizing. HARMONY 3 is a long-term, 3-year trial with unique design features that must be considered when interpreting results. First, up-titration was based on glucose thresholds established by protocol: the time point of titration was not prescribed or standardized, reflecting up-titration methods in clinical practice; thus, the efficacy and safety data reflect a mixture of 30-and 50-mg albiglutide doses and 2-and 4-mg glimepiride doses. In addition, there was no increased dose for placebo and sitagliptin despite patients who underwent the blinded up-titration procedure. Because of this design feature, many patients randomized to glimepiride and albiglutide were not receiving the maximum dose, as evidenced by the mean doses of each drug. Therefore, the maximum effect in these arms may not have been achieved, depending on the dose curve for each agent, and there is a possibility that the relationship between the arms may have shifted at higher doses.
Second, rescue medications were used in the program to permit patients to remain in the studies while receiving a blinded investigational product or control through 3 years. This represents a more "real-life" situation, where additional medications are added to regimens that are not meeting treatment goals. While the primary efficacy assessment was based on end points before rescue, the main safety assessment included data after rescue. These design features, however, may have complicated the interpretation of some results. Finally, interpretation of the proportion of patients reaching the treatment goal was complex; up-titration occurred at 7.5% and not 7.0%, and the full benefit of 50 mg may not be seen since the end point contains a mix of patients taking 30-and 50-mg albiglutide.
In conclusion, when added to metformin, albiglutide produced clinically and statistically significant reductions in HbA 1c and FPG at week 104 compared with placebo, sitagliptin, and glimepiride. Patients receiving albiglutide, sitagliptin, and placebo lost body weight through week 104, whereas patients taking glimepiride gained weight; the difference between albiglutide and glimepiride was statistically significant. Albiglutide was generally well tolerated, and rates of SAEs were similar across treatment groups. The most frequent AEs for albiglutide were largely consistent with the known profile for GLP-1RAs. The sponsor of the study participated in the study design, data collection, data review, data analysis, and writing of the report. All authors had full access to all the data in the study. The corresponding author reviewed the trial report (signatory investigator), had full access to all data in the study, and had final responsibility for the decision to submit for publication. 
